Spotlight
Video

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung

EMJ has 458 videos Subscribe Here

Loading........
Description: At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from LUX-lung 7, a randomised, open-label, phase 2b trial comparing afatinib to gefitinib in the first-line treatment setting with patients who are having epidermal growth factor receptor (EGFR) mutation-positive advanced adenocarcinoma of the lung.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 01/27/16
Added : 2 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.